2699607-48-0
Chemical Structure
Cobicistat-d8
Synonym(s): GS-9350-d8
- CAS No.: 2699607-48-0
- Formula:C40H45D8N7O5S2
- Molecular Weight:784.07
IUPAC Name: thiazol-5-ylmethyl ((2R,5R)-5-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-4-(morpholino-d8)butanamido)-1,6-diphenylhexan-2-yl)carbamate
InChIKey: ZCIGNRJZKPOIKD-OZLZWQNVSA-N
SMILES: CN(CC1=CSC(C(C)C)=N1)C(N[C@H](C(N[C@H](CC[C@H](CC2=CC=CC=C2)NC(OCC3=CN=CS3)=O)CC4=CC=CC=C4)=O)CCN5C([2H])(C([2H])(OC([2H])(C5([2H])[2H])[2H])[2H])[2H])=O
Biological Activity: Cobicistat-d8 (GS-9350-d8) is a deuterated version of Cobicistat (HY-10493). Cobicistat is a potent and selective inhibitor of cytochrome P450 3A (CYP3A) with IC50 values of 30-285 nM. Cobicistat is a pharmacokinetic enhancer that enhances the absorption of anti-HIV active molecules[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Cobicistat-d8 | Cobicistat-d8 (GS-9350-d8) is a deuterated version of Cobicistat (HY-10493). Cobicistat is a potent and selective inhibitor of cytochrome P450 3A (CYP3A) with IC50 values of 30-285 nM. Cobicistat is a pharmacokinetic enhancer that enhances the absorption of anti-HIV active molecules. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Cobicistat (Standard) | ≥98% | Cobicistat (Standard) is the analytical standard of Cobicistat. This product is intended for research and analytical applications. Cobicistat is a potent and selective inhibitor of cytochrome P450 3A (CYP3A) enzymes with IC50s of 30-285 nM. Cobicistat is a pharmacokinetic enhancer which increases the overall absorption of several HIV medications. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Cobicistat | 99.49% | Cobicistat is a potent and selective inhibitor of cytochrome P450 3A (CYP3A) enzymes with IC50s of 30-285 nM. Cobicistat is a pharmacokinetic enhancer which increases the overall absorption of several HIV medications. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Temesgen Z. Cobicistat, a pharmacoenhancer for HIV treatments. Drugs Today (Barc). 2013 Apr;49(4):233-7. [Content Brief]
- [3]. Lianhong Xu, et al. Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer. ACS Med. Chem. Lett., 2010, 1 (5), pp 209–213
